Immunotherapy shows long-term promise in aggressive lymphoma

Immunotherapy shows long-term promise in aggressive lymphoma. A leading-edge immunotherapy may extend survival for patients with one of the most aggressive forms of blood cancer, according to newly published five-year results from a major clinical trial in the Blood Journal.

A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.

Trechos de apoio da pauta: A leading-edge immunotherapy may extend survival for patients with one of the most aggressive forms of blood cancer, according to newly published five-year results from a major clinical trial in the Blood Journal. The clinical trial evaluated lisocabtagene maraleucel (liso-cel), a type of chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), a population with historically limited treatment options and poor outcomes after standard therapies fail.

• Ponto de atenção: immunotherapy.
• Ponto de atenção: shows.
• Ponto de atenção: long.

Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.